![Christopher Simms](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Simms
Företagsledare/Principal på
4D MOLECULAR THERAPEUTICS, INC.
Förmögenhet: - $ per 2026-08-31
Profil
Christopher Simms is Chief Commercial & Business Officer at 4D Molecular Therapeutics, Inc. starting in 2025.
Formerly, Mr. Simms was Chief Commercial Officer & Senior Vice President at IVERIC bio, Inc. Education includes an MBA from York University and an undergraduate degree from Memorial University of Newfoundland.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-03-25 | 0 ( -.--% ) | - $ | 2026-08-31 |
Aktiva positioner av Christopher Simms
| Företag | Position | Start |
|---|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Företagsledare/Principal | 2024-09-25 |
Tidigare kända positioner av Christopher Simms
| Företag | Position | Slut |
|---|---|---|
| IVERIC BIO, INC. | Företagsledare/Principal | - |
Christopher Simmss utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
22
Första gradens relationer
4
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
York University
 York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Memorial University of Newfoundland
 Memorial University of Newfoundland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IVERIC bio, Inc.
 IVERIC bio, Inc. BiotechnologyHealth Technology Operates as a science-driven biopharmaceutical company that develops novel treatments for retinal diseases | Health Technology |
4D Molecular Therapeutics, Inc.
 4D Molecular Therapeutics, Inc. BiotechnologyHealth Technology Designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions | Health Technology |
